WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 22, 2021 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 17, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Tracey L. McCain , Esq. to its Board of Directors.
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 16, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that in connection with the appointment of Kristen Harrington-Smith as ImmunoGen’s Senior Vice President
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 16, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer.
Triplet Demonstrated Manageable Safety Profile and Encouraging Activity, with 55% Objective Response Rate Across All Doses/Schedules in Escalation Data for IMGN632 in Frontline BPDCN Patients Will Also be Presented WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 4, 2021-- ImmunoGen Inc.
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 29, 2021 the compensation committee of the Company’s Board of Directors granted a
Top-Line Data from Pivotal SORAYA Trial Evaluating Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer on Track for Release this Quarter IMGN632 AML Combination Data to be Highlighted at ASH Annual Meeting PICCOLO, Single-Arm Study of Mirvetuximab in Platinum-Sensitive Ovarian Cancer,
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 14, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2021 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 22, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray , MD, FAAP to its Board of Directors.